Crinetics Pharmaceuticals, Inc. CRNX R2KR3KPHARMA
Company Overview
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Why Investors Should Care
Revenue has grown at a 33.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $7.70M (+640.7% YoY); net profit $-465.32M.
- Trailing 12 Months Year-on-year growth — revenue +2336.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 33.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 33.05% |
| 1 Year: | 2,336.30% |
Stock Price Performance
| 1 Year: | +182.32% |
| 6 Months: | +115.01% |
| 3 Months: | +156.72% |
| 1 Month: | +1.30% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)89.79 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 33.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- RSI at 90 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CRNX Crinetics Pharmaceuticals, Inc. R2KR3KPHARMA | 84.95 | -16.82 | $9.01B | 0.00% | -49.63% | -42.45% | 33.05% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.00K | 832.00K | 640.00K | 528.00K | 442.00K | 657.00K | 548.00K | 781.00K | 367.00K | - | 505.00K | 321.00K | 71.00K | - | - | 0 | - | 0 | 3.13M | 439.00K | 458.00K | 2.68M | 988.00K | 346.00K | 640.00K | 399.00K | 0 | - | 361.00K | 1.03M | 143.00K | 6.16M | 10.73M | 25.12M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 200.00K | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 361.00K | - | - | - | 10.53M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 111.77M | 130.14M | 142.73M | 138.75M | 150.91M | - |
| Operating Income | - | -1.64M | -2.37M | - | -5.53M | -5.68M | -8.07M | - | -10.04M | -13.35M | -15.23M | - | -17.78M | -16.93M | -18.45M | -22.92M | -26.09M | -27.81M | -33.83M | -43.05M | -43.45M | -47.98M | -52.99M | -58.98M | -73.53M | -82.78M | -87.80M | - | -111.41M | -129.11M | -142.59M | -133.67M | -140.38M | -132.46M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -110.48M | -128.15M | -141.57M | -132.67M | -139.22M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -96.77M | -115.64M | -130.09M | -122.64M | -127.84M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.61M | -1.65M | -2.38M | -2.52M | -5.46M | -5.57M | -7.59M | -8.49M | -9.02M | -12.43M | -14.43M | -14.55M | -17.36M | -16.49M | -18.32M | -22.90M | -26.09M | -27.85M | -34.63M | -42.38M | -41.92M | -45.99M | -50.98M | -57.46M | -66.93M | -74.06M | -76.83M | - | -96.77M | -115.64M | -130.09M | -122.81M | -127.84M | -120.86M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.70 | -0.73 | -0.73 | -0.81 | -0.78 | -0.85 | -0.94 | -1.01 | -0.93 | -0.94 | -0.96 | - | -1.04 | -1.23 | -1.38 | -1.29 | -1.23 | -1.14 |
| R&D Expense | 2.06M | 2.08M | 2.52M | 2.56M | 4.72M | 5.22M | 6.89M | 7.65M | 7.25M | 10.29M | 11.82M | 12.14M | 13.86M | 12.61M | 13.70M | 17.58M | 20.49M | 21.58M | 28.25M | 32.99M | 31.99M | 38.47M | 40.64M | 43.84M | 53.34M | 58.34M | 61.91M | - | 76.24M | 80.30M | 90.46M | - | 100.08M | 99.85M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 589.00K | 2.04M | 2.43M | 1.19M | 71.00K | 0 | 0 | 4.01M | 1.04M | 7.70M |
| Operating Income | -6.04M | -9.13M | -28.71M | -53.83M | -74.95M | -107.70M | -167.88M | -222.61M | -338.85M | -516.77M |
| Net Income | -6.02M | -9.16M | -27.11M | -50.42M | -73.81M | -107.64M | -163.92M | -214.53M | -298.41M | -465.32M |
| Diluted EPS | - | - | - | - | -2.42 | -2.80 | -3.15 | -3.69 | -3.69 | -4.95 |
| R&D Expense | 5.10M | 9.23M | 24.48M | 41.51M | 57.00M | 84.25M | 130.22M | 168.53M | 240.16M | 332.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 15.60M | 171.41M | 130.38M | 183.44M | 351.01M | 352.18M | 635.35M | 1.43B | 1.13B |
| Total Equity | -463.00K | -6.20M | -15.02M | 160.22M | 117.14M | 168.92M | 331.94M | 316.33M | 539.11M | 1.32B | 992.08M |
| Cash & Equivalents | - | - | 14.19M | 44.97M | 40.33M | 93.09M | 200.69M | 32.67M | 54.90M | 264.55M | 101.54M |
| Total Liabilities | - | - | 920.00K | 11.19M | 13.24M | 14.53M | 19.07M | 35.85M | 96.25M | 109.79M | 134.17M |
| Current Liabilities | - | - | 897.00K | 7.92M | 8.34M | 10.49M | 15.99M | 27.72M | 43.94M | 59.68M | 85.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.47M | -9.48M | -19.46M | -46.38M | -62.03M | -88.59M | -115.20M | -168.60M | -230.19M | -377.92M |
| Investing Cash Flow | -190.00K | -304.00K | -119.46M | 41.67M | 217.00K | -56.48M | -173.98M | -200.41M | -574.82M | 173.91M |
| Financing Cash Flow | -53.00K | 11.82M | 170.20M | 67.00K | 114.57M | 252.68M | 121.96M | 391.24M | 1.01B | 40.61M |
| Capital Expenditure | -190.00K | -304.00K | -1.06M | -492.00K | -186.00K | -436.00K | -1.66M | -4.69M | -3.84M | -5.76M |
| Free Cash Flow | -5.66M | -9.78M | -20.52M | -46.87M | -62.21M | -89.02M | -116.86M | -173.29M | -234.04M | -383.68M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -1,026.1% | -446.3% | -1,182.5% | -4,512.3% | -105,567.6% | - | - | -5,547.2% | -32,613.5% | -6,714.8% |
| Net Margin % | -1,021.9% | -447.8% | -1,116.8% | -4,226.5% | -103,960.6% | - | - | -5,345.9% | -28,720.7% | -6,046.2% |
| ROE % | 97.0% | 61.0% | -16.9% | -43.0% | -43.7% | -32.4% | -51.8% | -39.8% | -22.5% | -46.9% |
| ROCE % | - | -62.1% | -17.6% | -44.1% | -43.3% | -32.1% | -51.7% | -37.6% | -24.6% | -49.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.93% | 15.84M | $1.34B |
| 2 | Blackrock Inc. | 9.20% | 9.76M | $827.95M |
| 3 | Farallon Capital Management LLC | 8.48% | 8.99M | $762.64M |
| 4 | Wellington Management Group, LLP | 6.72% | 7.13M | $605.00M |
| 5 | Driehaus Capital Management, LLC | 6.09% | 6.46M | $548.37M |
| 6 | Price (T.Rowe) Associates Inc | 5.86% | 6.21M | $527.08M |
| 7 | Vanguard Portfolio Management LLC | 4.56% | 4.83M | $410.00M |
| 8 | Vanguard Capital Management LLC | 4.47% | 4.75M | $402.59M |
| 9 | Jupiter Topco LLC | 4.30% | 4.56M | $386.67M |
| 10 | Geode Capital Management, LLC | 2.57% | 2.73M | $231.41M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CRNX
Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPYzZ5NmI4bGViby10MVphV0Q2LUlBYzB5V01wUjI5cFFmWHVROGN4SjI1Mzlkd3VxS0NzbmFfRm5kZkZkU3o5S0tXSnMxMEMzLV8weG1GZUF1aDF1Yll0bDlyU1ZpNERwbUlncjNONW5FWGdjWGtFWDNTVUxqclFVTjdZRUlFOFNGNzJIRk…
$85-per-share buyout shows how Crinetics (CRNX) insiders were paid in Vertex deal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPdElEODI2cDlvd2c5WE5hRG1pak9ReEZSeHU0c0lOVGpnZWR0c1RaN2pTMm81QWdJLTU1V0J2ZXRBWWIweWlyQUtBVGRGQ1NoR3U2eXRBS2h5VnJrLVdzMHdvM1dtTW9za3k4aVhWYl8zcTl6UFpSaDYxSE1MbVJmeXhsNHFndk9uZ0tLMk…
Crinetics Pharmaceuticals (CRNX) Stock Looks Overvalued Despite Strong 3 Year Returns - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxNWTBjX2NRSEdJSWdMQlQ0emVwU1R1TGtjTzNuQ3RhbUM0d1g5ck9LUXRKcTl1LUY4V3lNeTlqUmlvOWx6c2VSdjZWenpZMXVGV0FqSElHNUdMTkRZMUxfbllBanZFZFhoM3RRZW9hYVRkbnlwRURGNmRQOUwwWlo4WnNDbEtWZW9OYnNFU3…
Crinetics (CRNX) Stock Could Be Overvalued After Its 113% Run - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNZGREMGQyYkpzRDNpVTItb3ZUMDV0TGMtcExzN0Q5NWR5a2pqX0FRcDM0dkM4XzdMcTF1OGltOUVMZTNfQlRsVWNLZ01CalNkNHlYQVdsSUFaLW5aMTktOUlLdUdKeDdKazIyZXdtT0ltVV9ZT2tPd3lZbzEzaHlLc0FvcFFid2xfRVN5Yn…
Crinetics (NASDAQ: CRNX) director’s stock and options converted to $85 cash in Vertex deal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZ1A0djQyaGd3YTA4NkliTDJqMUJRZjdmVFpEaEFpVk5rYjlyaVQ4WXc2RXAwQ0NDeTY3SlhSYk1vc05tS0t1QUthS0dCYlVGenRjcXlkRjd2SHNkQlZWdzVhRlY3ekRFcC0xUlZrempYRnJNWXZfd1Jva1hwWFNUSzd5MEVXQ1g3Vm80VV…
What Does Crinetics Pharmaceuticals (CRNX) Delisting Mean After The Takeover Closed? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxPZVpQN0YtaXptbThUTkpPVXFHNHM5RUozZDBkZ2t2NjNTRVhVOExFeWRocXlWcVBzWW9DcXBFbndHYThRSFhlYjF2Z0dQS3JXY3A0X0JydFM3UjdVakw5aURJUTJzcUc2N3pzdVRqWlFmRjZnZ3B4NnNTSlZMX2k2Z2szN2Q4eVV5QUI0SV…
CRNX — Frequently Asked Questions
What is the current share price of Crinetics Pharmaceuticals, Inc. (CRNX)?
As of 2026-09-07 16:24 PDT, Crinetics Pharmaceuticals, Inc. (CRNX) trades at $84.95 on NasdaqGS. Its 52-week range is $29.09 to $84.95.
What is the market capitalisation of CRNX?
Crinetics Pharmaceuticals, Inc. (CRNX) has a market capitalisation of $9.01B on NasdaqGS.
What is the P/E ratio of CRNX?
CRNX trades at a trailing price-to-earnings (P/E) ratio of -16.82. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.46.
What is the return on equity (ROE) of CRNX?
CRNX has a return on equity (ROE) of -42.45%. Its return on capital employed (ROCE) is -49.63%.
Is CRNX a good stock to buy?
This page provides a data-driven analysis of Crinetics Pharmaceuticals, Inc. (CRNX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.